Product liability House/Senate conference unlikely until next year.
This article was originally published in The Gray Sheet
PRODUCT LIABILITY HOUSE/SENATE CONFERENCE NOT LIKELY UNTIL NEXT YEAR due to Senate leadership concerns that attempting recon-ciliation now would result in a conference bill that retains much of the character of the House's more rigorous version. The House version (HR 956), passed March 10, differs from the Senate legislation (S 565), approved May 10, in that it includes both an FDA defense and a cap of non-economic ("pain and suffering") damages at $250,000 for health care lawsuits which would supersede state laws that set a higher cap on non-economic damage awards.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.